155 related articles for article (PubMed ID: 2468794)
21. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
22. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
23. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study.
Morote Robles J; Ruibal Morell A; Palou Redorta J; de Torres Mateos JA; Soler Roselló A
Eur Urol; 1988; 14(5):360-6. PubMed ID: 2458936
[TBL] [Abstract][Full Text] [Related]
24. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
[TBL] [Abstract][Full Text] [Related]
25. The present role of prostatic specific antigen (PSA) as a tumor marker in carcinoma of the prostate.
Parra RO
Mo Med; 1991 Jun; 88(6):349-52. PubMed ID: 1712422
[TBL] [Abstract][Full Text] [Related]
26. Prostate specific antigen after irradiation for prostatic carcinoma.
Kaplan I; Prestidge BR; Cox RS; Bagshaw MA
J Urol; 1990 Nov; 144(5):1172-5; discussion 1175-6. PubMed ID: 1700144
[TBL] [Abstract][Full Text] [Related]
27. The predictive significance of substaging stage A prostate cancer (A1 versus A2) for volume and grade of total cancer in the prostate.
Voges GE; McNeal JE; Redwine EA; Freiha FS; Stamey TA
J Urol; 1992 Mar; 147(3 Pt 2):858-63. PubMed ID: 1371561
[TBL] [Abstract][Full Text] [Related]
28. Comparison of enzyme-linked immunosorbent assay and radioimmunoassay for prostate-specific acid phosphatase in prostatic disease.
Griffiths J; Rippe DF; Panfili PR
Clin Chem; 1982 Jan; 28(1):183-6. PubMed ID: 7055908
[TBL] [Abstract][Full Text] [Related]
29. Nondetectable prostate-specific antigen in moderately differentiated adenocarcinoma of prostate.
Daugherty RL; Cos LR; Keller JW; di Sant'Agnese A
Urology; 1992 Jun; 39(6):552-5. PubMed ID: 1377434
[TBL] [Abstract][Full Text] [Related]
30. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
[TBL] [Abstract][Full Text] [Related]
31. Immunologically measured serum markers and their role in the management of prostate cancer.
Powell P; Neal D; Gibb I; Wilson L; Hall R
Eur Urol; 1988; 15(1-2):48-53. PubMed ID: 2463921
[TBL] [Abstract][Full Text] [Related]
32. Long-term followup results after expectant management of stage A1 prostatic cancer.
Zhang G; Wasserman NF; Sidi AA; Reinberg Y; Reddy PK
J Urol; 1991 Jul; 146(1):99-102; discussion 102-3. PubMed ID: 1711592
[TBL] [Abstract][Full Text] [Related]
33. Value of prostate-specific antigen measurements in predicting lymph node involvement in prostatic cancer.
Arai Y; Yoshiki T; Yamabe H; Yoshida O
Urol Int; 1990; 45(6):356-60. PubMed ID: 1705062
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy.
Zagars GK; von Eschenbach AC; Ayala AG
Cancer; 1993 Sep; 72(5):1709-25. PubMed ID: 7688659
[TBL] [Abstract][Full Text] [Related]
35. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.
Shih WJ; Gross K; Mitchell B; Collins J; Wierzbinski B; Magoun S; Ryo UY
J Natl Med Assoc; 1992 Dec; 84(12):1049-50. PubMed ID: 1284282
[TBL] [Abstract][Full Text] [Related]
36. Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy.
Brawer MK; Rennels MA; Nagle RB; Schifman R; Gaines JA
Am J Clin Pathol; 1989 Dec; 92(6):760-4. PubMed ID: 2480060
[TBL] [Abstract][Full Text] [Related]
37. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
38. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
McLaren DB; McKenzie M; Duncan G; Pickles T
Cancer; 1998 Jan; 82(2):342-8. PubMed ID: 9445192
[TBL] [Abstract][Full Text] [Related]
39. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume.
Schmid HP; McNeal JE; Stamey TA
Cancer; 1993 Mar; 71(6):2031-40. PubMed ID: 7680277
[TBL] [Abstract][Full Text] [Related]
40. Critical assessment of prostate cancer staging.
Graham SD
Cancer; 1992 Jul; 70(1 Suppl):269-74. PubMed ID: 1376195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
